Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study
European Journal of Neurology · 2024
DOI: 10.1111/ene.16410 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Laura Zanandrea und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Purpose Fremanezumab, a monoclonal antibody targeting the calcitonin gene‐related peptide for migraine prevention, is available in monthly (225 mg) and quarterly (675 mg) doses. Previous studies showed efficacy and safety for both regimens, but a real‐life comparison is lacking. This study aimed to compare the effectiveness and safety of monthly and quarterly fremanezumab in a real‐life setting.
Methods
This Italian, prospective, multicenter study enrolled 95 migraine patients. During a 3‐month treatment period, patients received either monthly or quarterly fremanezumab (49 monthly, 46 quarterly). A 6‐month treatment period involved 79 patients (43 monthly, 36 quarterly). Monthly headache (MHD) and migraine days (MMD), number of days (AMD) and pills (AMP) of acute medication intake, and Headache Impact Test (HIT‐6), Migraine Disability Assessment (MIDAS) test, and Numeric Rating Scale (NRS) scores were recorded at baseline and after 3 and 6 months of treatment. Adverse events (AEs), responder rates, and medication overuse were also investigated.
Results
Both monthly and quarterly treatments led to significant reductions in MMD, MHD, AMP, AMD, HIT‐6, MIDAS, and NRS scores after 3 and 6 months. The monthly regimen exhibited a slightly greater reduction in MMD and MHD after the first quarter, with no significant difference observed after 6 months. The most common AE was transient injection‐site reaction, without between‐group differences. Responder rates and resolution of medication overuse did not significantly differ between the groups.
Conclusions
Both monthly and quarterly regimens were effective and safe, with a tendency for an advantage of the monthly regimen only in the first quarter of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Unit of Headache and Neurosonology, Department of Medicine and Surgery, University Campus Bio-Medico di Roma, Rome, Italy.
- Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
ORCID-Profile: Roberta Messina, Fabrizio Vernieri, Valentina Favoni, Massimo Filippi
Zitieren
APA
Zanandrea, L., Messina, R., Cetta, I., Genovese, F., Guerrieri, S., Vernieri, F., Altamura, C., Cevoli, S., Favoni, V., Colombo, B., & Filippi, M. (2024). Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study. European Journal of Neurology. https://doi.org/10.1111/ene.16410
Vancouver
Zanandrea L, Messina R, Cetta I, Genovese F, Guerrieri S, Vernieri F, et al. Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study. European Journal of Neurology. 2024. doi:10.1111/ene.16410
BibTeX
@article{Zanandrea2024,
author = {Zanandrea, Laura and Messina, Roberta and Cetta, Ilaria and Genovese, Federica and Guerrieri, Simone and Vernieri, Fabrizio and Altamura, Claudia and Cevoli, Sabina and Favoni, Valentina and Colombo, Bruno and Filippi, Massimo},
title = {Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16410}
}
EUVIMED